MADRID, Feb. 3 /CNW/ - Digna Biotech and the Centro de Investigacion
Medica Aplicada (CIMA) de la Universidad de Navarra announced today
that the European Union (EU) has finalized a EUR 3.3 million grant to
AIPGENE consortium. Digna Biotech and CIMA will receive, as members of
the consortium, EUR 0.5 and EUR 0.8 million respectively for the
clinical development of a gene therapy product for Acute Intermittent
The AIPGENE consortium is led by CIMA (University of Navarra), and in
addition to Digna Biotech includes Clinica Universidad de Navarra,
Amsterdam Molecular Therapeutics (AMT), Stockholms Lans Landsting,
Deutsches Krebsforschungszentrum and Servicio Madrileno de Salud.
As part of the AIPGENE grant, Digna Biotech and CIMA will complete a
Phase I/II study in humans. With the support of all AIPGENE partners,
Digna Biotech anticipates AIP patient enrolment in the trial in early
Under a co-development agreement, Digna Biotech transferred to AMT
global rights to develop and commercialize this adeno-associated based
gene therapy vector for acute intermittent porphyria. AMT was granted
Orphan Drug Designation for this vector.
About Acute Intermittent Porphyria
Acute intermittent porphyria is a rare genetic disease where mutations
in the porphobilinogen deaminase (PBGD) gene results in insufficient
activity of a protein necessary for heme synthesis that produce a wide
variety of problems including acute and severe abdominal pain and
psychiatric and neurological symptoms. There is currently no cure for
this condition and the disease is typically progressive.
CIMA (University of Navarra) brings pure research closer to its clinical
application, carrying out high-quality scientific work in the service
of humankind, combating diseases that cause great suffering and for
which no cure has yet been discovered.
About Digna Biotech and CIMA
Digna Biotech is a biotechnological company focused on the development
products originated from CIMA. Currently, Digna's portfolio includes 3
more products in clinical development: P144, a peptide inhibiting
TGF-beta 1 that has completed Phase II in patients with scleroderma,
Interferon alpha 5 for the treatment of hepatitis C infection in Phase
I/II) and cardiotrophin for liver resection that will start Phase I in
Further information can be found at http://www.cima.es and http://www.dignabiotech.com.
SOURCE Digna Biotech
For further information:
Pablo Ortiz, CEO Digna Biotech, Tel: +34-91-185-2510, firstname.lastname@example.org